485 related articles for article (PubMed ID: 21841159)
21. Primary Cutaneous Anaplastic Large Cell Lymphoma (pcALCL) in the Elderly and the Importance of Sport Activity Training.
Sica A; Vitiello P; Ronchi A; Casale B; Calogero A; Sagnelli E; Costa Nachtigal G; Troiani T; Franco R; Argenziano G; Moscarella E; Sagnelli C
Int J Environ Res Public Health; 2020 Jan; 17(3):. PubMed ID: 32013101
[TBL] [Abstract][Full Text] [Related]
22. Understanding Cell Lines, Patient-Derived Xenograft and Genetically Engineered Mouse Models Used to Study Cutaneous T-Cell Lymphoma.
Gill RPK; Gantchev J; Martínez Villarreal A; Ramchatesingh B; Netchiporouk E; Akilov OE; Ødum N; Gniadecki R; Koralov SB; Litvinov IV
Cells; 2022 Feb; 11(4):. PubMed ID: 35203244
[TBL] [Abstract][Full Text] [Related]
23. Is immunohistochemical expression of GATA3 helpful in the differential diagnosis of transformed mycosis fungoides and primary cutaneous CD30-positive T cell lymphoproliferative disorders?
Collins K; Gu J; Aung PP; Nagarajan P; Curry JL; Huen A; Ivan D; Prieto VG; Tetzlaff MT; Duvic M; Miranda RN; Vega F; Torres-Cabala CA
Virchows Arch; 2021 Aug; 479(2):377-383. PubMed ID: 33604757
[TBL] [Abstract][Full Text] [Related]
24. A new era for cutaneous CD30-positive T-cell lymphoproliferative disorders.
Kempf W
Semin Diagn Pathol; 2017 Jan; 34(1):22-35. PubMed ID: 27993440
[TBL] [Abstract][Full Text] [Related]
25. Primary Cutaneous CD30+ Lymphoproliferative Disorders in a Patient with Severe Atopic Dermatitis: Is There a Causative Link?
Zychowska M; Woźniak Z; Maj J
Acta Derm Venereol; 2018 Jan; 98(1):123-125. PubMed ID: 28952656
[No Abstract] [Full Text] [Related]
26. Novel use of 308-nm excimer laser to treat a primary cutaneous CD30+ lymphoproliferative nodule.
Meisenheimer JL
J Drugs Dermatol; 2007 Apr; 6(4):440-2. PubMed ID: 17668543
[TBL] [Abstract][Full Text] [Related]
27. A case of lymphomatoid papulosis type E in a young adult: An uncommon entity.
Rajashekara Swamy M; Pollock S; J Goldberg L; Shen L
J Cutan Pathol; 2021 May; 48(5):694-700. PubMed ID: 33533041
[TBL] [Abstract][Full Text] [Related]
28. Immunohistochemical analysis of CD30-positive lymphoproliferative disorders for expression of CD95 and CD95L.
Sigel JE; Hsi ED
Mod Pathol; 2000 Apr; 13(4):446-51. PubMed ID: 10786813
[TBL] [Abstract][Full Text] [Related]
29. Polymorphism of the CD30 promoter microsatellite repressive element is associated with development of primary cutaneous lymphoproliferative disorders.
Franchina M; Kadin ME; Abraham LJ
Cancer Epidemiol Biomarkers Prev; 2005 May; 14(5):1322-5. PubMed ID: 15894695
[TBL] [Abstract][Full Text] [Related]
30. MUM1 expression in cutaneous CD30+ lymphoproliferative disorders: a valuable tool for the distinction between lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma.
Kempf W; Kutzner H; Cozzio A; Sander CA; Pfaltz MC; Müller B; Pfaltz M
Br J Dermatol; 2008 Jun; 158(6):1280-7. PubMed ID: 18410414
[TBL] [Abstract][Full Text] [Related]
31. A novel recurrent NPM1-TYK2 gene fusion in cutaneous CD30-positive lymphoproliferative disorders.
Velusamy T; Kiel MJ; Sahasrabuddhe AA; Rolland D; Dixon CA; Bailey NG; Betz BL; Brown NA; Hristov AC; Wilcox RA; Miranda RN; Medeiros LJ; Jeon YK; Inamdar KV; Lim MS; Elenitoba-Johnson KS
Blood; 2014 Dec; 124(25):3768-71. PubMed ID: 25349176
[TBL] [Abstract][Full Text] [Related]
32. Primary cutaneous anaplastic large cell lymphoma.
Brown RA; Fernandez-Pol S; Kim J
J Cutan Pathol; 2017 Jun; 44(6):570-577. PubMed ID: 28342276
[TBL] [Abstract][Full Text] [Related]
33. Primary cutaneous CD30+ lymphoproliferative disorders with DUSP22 translocation.
Montes-Moreno S
Pathologie (Heidelb); 2023 Dec; 44(Suppl 3):136-139. PubMed ID: 38010388
[TBL] [Abstract][Full Text] [Related]
34. Spectrum of primary cutaneous CD30 (Ki-1)-positive lymphoproliferative disorders. A proposal for classification and guidelines for management and treatment.
Willemze R; Beljaards RC
J Am Acad Dermatol; 1993 Jun; 28(6):973-80. PubMed ID: 8388410
[TBL] [Abstract][Full Text] [Related]
35. Lack of the t(2;5) or other mutations resulting in expression of anaplastic lymphoma kinase catalytic domain in CD30+ primary cutaneous lymphoproliferative disorders and Hodgkin's disease.
Wood GS; Hardman DL; Boni R; Dummer R; Kim YH; Smoller BR; Takeshita M; Kikuchi M; Burg G
Blood; 1996 Sep; 88(5):1765-70. PubMed ID: 8781433
[TBL] [Abstract][Full Text] [Related]
36. Acitretin combined with NB-UVB in the treatment of cutaneous CD30-positive anaplastic large cell lymphoma.
Xu H; Liu Q; Li YM; Ma H; Hu HM
Dermatol Ther; 2019 Mar; 32(2):e12834. PubMed ID: 30659723
[TBL] [Abstract][Full Text] [Related]
37. Lymphomatoid papulosis: Treatment response and associated lymphomas in a study of 180 patients.
Wieser I; Oh CW; Talpur R; Duvic M
J Am Acad Dermatol; 2016 Jan; 74(1):59-67. PubMed ID: 26518172
[TBL] [Abstract][Full Text] [Related]
38. Most primary cutaneous CD30-positive lymphoproliferative disorders have a CD4-positive cytotoxic T-cell phenotype.
Kummer JA; Vermeer MH; Dukers D; Meijer CJ; Willemze R
J Invest Dermatol; 1997 Nov; 109(5):636-40. PubMed ID: 9347791
[TBL] [Abstract][Full Text] [Related]
39. Death receptor apoptosis signaling mediated by FADD in CD30-positive lymphoproliferative disorders involving the skin.
Clarke LE; Bayerl MG; Bruggeman RD; Mauger D; Ioffreda MD; Abou-Elella A; Helm KF
Am J Surg Pathol; 2005 Apr; 29(4):452-9. PubMed ID: 15767797
[TBL] [Abstract][Full Text] [Related]
40. Primary CD30-positive cutaneous T-cell lymphomas and lymphomatoid papulosis frequently express cytotoxic proteins.
Boulland ML; Wechsler J; Bagot M; Pulford K; Kanavaros P; Gaulard P
Histopathology; 2000 Feb; 36(2):136-44. PubMed ID: 10672058
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
